




A Clinical stage
Med-Tech Company



→ INVITATION

to subscribe for shares in Ambusol AB (publ)

October 6 - November 17, 2025

Important Information

An investment in securities involves certain risks, and investors are urged to particularly read the section "Risk Factors" in the full Memorandum. Before making an investment decision, the investor must rely on their own professional advisors and carefully evaluate and consider the investment decision. Investors may only rely on the information in the Memorandum and any supplements to the Memorandum. No person is authorized to provide any other information or make any other statements than those contained in the Memorandum. If such information or statements are nevertheless provided, they should not be considered as approved by the Company, which does not take responsibility for such information or statements. The Memorandum can be downloaded from www.Ambusol.se or from www.Aqurat.se

→ Ambusol in short and the team

AMBUSOL AB (PUBL) is a Swedish company that was incorporated in 2023, after several decades of research by Prof. Gunnar Ronquist and his team. Ambusol's leadership team blends deep scientific expertise with entrepreneurial drive and leading innovation in the treatment of Glioblastoma (GBM). With a strong background in medicine, biotechnology, and product development, they have contributed to over 500 scientific publications, launched 3 medicines, and brought 10 Med -Tech products to the global market.



Prof. Gunnar Ronquist
Innovator & Founder

Scientific Achievements

Inventor of the Ambusol oncology treatment.

Discovered Prostatomes, earning the Royal Society of Science Award in 2014.

Authored over 360 peer-reviewed scientific papers.

Supervised 35 Ph.D. students throughout his academic career.

Published in esteemed anti cancer research.

Co-authored biological transport book with H.N - Christensen.

Key Contributions

Leading the development of Ambusol's oncology treatment.

Advocating for more humane and effective cancer care, with a focus on improving patient quality of life.

Expanding Ambusol's research into other high-mortality cancers, including pancreatic and prostate cancer, with promising early results.

Championing a global vision to replace outdated cancer therapies with cost-effective, patient-centered alternatives.

Professional Background

Founder of Ambusol, a company dedicated to developing innovative, non-toxic therapies for glioblastoma.

Former Head Physician at University Hospital, Uppsala, Sweden.

Licensed physician in both Sweden and the United States.

Consultant for Pharmacia in Uppsala, Sweden.

Served as Editor-in-Chief of the Uppsala Journal of Medical Sciences (2012).

→ Management, Board & Advisors



Prof. Owe Orwar

Senior Advisor to the Board

With over 20 years of industry experience, Owe has successfully brought medicines, medical devices and medtech products to global markets. He has held key roles at major companies such as Sanofi and has multiple approved medicines to his name. Owe holds a PhD from Stanford University.



Göran Ronquist

Founder & Member of the Board

As a prominent chemist and researcher, Göran is the core of Ambusol's research and development. Göran has previously worked as a researcher at Oblique Therapeutics, SLU, and Uppsala University. Göran's deep knowledge and passion for innovation are a vital part of Ambusol's ongoing research and development.



Frederic Telander

Founder & Chairman of the Board

Frederic is a seasoned corporate leader and entrepreneur with financial background and over 30 years of experience in senior roles across both public and private companies. He has led IPOs in the UK and Sweden, including Gas Turbine Efficiency Plc, Soltech Energy, and Gigasun, where he currently serves as Chairman.

As Chairman of Ambusol, Frederic plays a key role in strategic financial planning and investor exit strategies. His leadership and extensive business acumen are vital to Ambusol's continued growth and success.



Holger Ronquist

Founder & Member of the Board

International businessman with combined technical and legal expertise. Formerly held roles at Ericsson and within government agencies. At Ambusol, he supports client negotiations and regulatory approvals.



Maximilian Telander

Founder & CEO

With a solid financial background from Warwick Business School and experience at Deutsche Bank, he brings strong expertise to his role as CEO of Ambusol. His financial insight and strategic leadership play a key role in shaping the company's business direction, strengthening its go-to-market plan, and supporting long-term growth.

→ Problem and Validation

GBM IS A DEADLY brain cancer with poor survival prognosis, but Ambusol's treatment is proven and has shown patients living years beyond initial prognosis. Early clinical results and strong interest from leading cancer hospitals (especially in China) confirms its breakthrough potential.

OVERVIEW

- GBM is a highly aggressive brain cancer with a market size of 3.6B USD in 2024, rising to 8.3B USD by 2034.
- Median survival for GBM is only 12–16 months with current treatments.
- Recurrence is almost universal, and side effects of traditional treatment methods are severe.
- There is urgent demand for new, effective therapies with fewer side effects.

THE PROBLEM

- Current GBM treatments offer limited survival and harsh side effects; most patients relapse quickly.
- Traditional therapies last 15 months with major side effects; **Ambusol's treatment is shorter and well-tolerated.**
- Blood-Brain Barrier Limitations: Many drugs cannot effectively reach tumor cells due to the protective blood-brain barrier, reducing treatment efficacy.
- Tumor Heterogeneity: GBM tumors are genetically and biologically diverse, making it difficult for a single therapy to target all cancerous cells.
- Resistance to Therapy: GBM quickly adapts and develops resistance to standard treatments like radiation and Temozolomide, leading to treatment failure.

AMBUSOL'S TREATMENT - VALIDATION AND INTEREST

- Initial clinical studies in Sweden showed Ambusol is safe and well-tolerated in treated patients.
- Remarkable survival in both cases provides strong early proof of efficacy.
- In June 2025, four top Chinese hospitals showed strong interest in Ambusol.
- International validation and clinical results highlight Ambusol's global potential.
- Ambusol successfully treated two terminally ill GBM patients: a woman with no recurrence after 7.5 years, and a man after 2.5 years.
- These cases show that Ambusol's treatment dramatically extends survival for GBM patients.

→ Ambusol Treatment Innovation – Proven Cases

AMBUSOL'S TREATMENT offers a groundbreaking approach with precise targeting, shorter duration, minimal side effects, and remarkable patient outcomes.

PATENTED CATHETER TECHNOLOGY

A **unique catheter system** delivers Ambusol's proprietary treatment fluid directly into the tumor, enabling precise targeting and simultaneous removal of necrotic tissue for enhanced efficacy.

ARTIFICIAL AMINO ACID

Ambusol's **proprietary artificial amino acid** targets metabolic vulnerabilities in glioblastoma cells, causing them to self-destruct while sparing healthy brain tissue with 400% uptake in tumor cells.

TREATMENT DURATION & SIDE EFFECTS

Treatment lasts **approximately 1 week** with no observed adverse side effects, a major improvement over traditional 13-month therapies that cause significant patient discomfort.

Patient Success Stories




- **Treated in 2017**
- **7.5 Years Cancer-Free**
- 36-year-old female
- Recurrent brain tumor detected just 3 months after prior treatment
- Tumor successfully removed and treated with our novel regimen
- **No recurrence after 7.5 years of follow-up**
- Outstanding long-term remission in a high-risk patient.



- **Treated in 2022**
- **2,5 years Cancer-Free**
- 58-year-old male
- Diagnosed with a highly aggressive glioblastoma
- Tumor recurred within 3 months, but was treated using our approach
- **No recurrence after 2.5 years of follow-up**
- Remarkable disease control in an aggressive tumor type

→ Technology Behind The Ambusol Treatment

AMBUSOL'S ARTIFICIAL amino acid combined with patented catheter technology enables precise, targeted treatment of glioblastoma tumors, maximizing efficacy while minimizing harm to healthy brain tissue.



ARTIFICIAL AMINO ACID INNOVATION

Ambusol's treatment uses an artificial amino acid that cancer cells uptake four times more than healthy cells, triggering self-destruction of tumor cells while sparing normal brain tissue.



PATENTED CATHETER DELIVERY SYSTEM

A specialized catheter delivers and extracts the treatment fluid directly into the tumor, allowing localized, high-precision drug administration while simultaneously clearing necrotic tissue.



ADVANTAGES OVER TRADITIONAL THERAPIES

The treatment requires only one week (7 days) with no side effects, contrasting with conventional methods lasting about 13 months and causing significant adverse effects.

→ Partnering hospitals

THE FOUR LEADING hospitals in China have expressed strong interest in Ambusol's GBM Proof-of-Concept studies, demonstrating both readiness and strategic alignment for collaborative clinical research. **China represents one of the world's largest glioblastoma markets, with over 50,000 cases annually compared to 26,000 in Europe and 12,000 in the US.**

Pictures below show the Ambusol team together with the respective professors and leading neurosurgical teams at each hospital in June 2025.



TIANTAN HOSPITAL (BEIJING)

- Strong interest in conducting GBM clinical trials focusing on novel therapies.
- Recognized as a leading neurosurgery center with extensive experience in treating GBM patients.
- Committed to leveraging its advanced surgical and research capabilities to support trial success.



HUASHAN HOSPITAL (SHANGHAI)

- Experienced in managing and executing global clinical trials with rigorous standards.
- Focused on translational GBM research to bridge laboratory discoveries to clinical applications.
- Keen to enhance international collaborations for innovative trial designs and data sharing.



XIANGYA HOSPITAL (CHANGSHA)

- Eager to adopt cutting-edge and innovative GBM therapies in clinical practice.
- Supports capacity-building initiatives to strengthen clinical trial infrastructure and expertise.
- Committed to integrating new treatment modalities with existing clinical care pathways.



RENJI HOSPITAL (SHANGHAI)

- Expressed strong interest in joining a collaborative GBM research consortium to pool resources.
- Open to integrating novel therapies and trial protocols into their clinical programs.
- Focused on creating a multi-institutional platform for GBM research and rapid patient recruitment.

→ Why These Hospitals for Ambusols Proof Of Concept?

THESE LEADING HOSPITALS offer high patient volumes, expertise in neurosurgery, strong infrastructure for clinical trials, and a proven track record of international collaborations, making them ideal for our Proof-of-Concept study. Each hospital intends to contribute 4–10 patients and cover all hospital-related costs and surgery, while Ambusol provides the equipment and guidance on how the treatment should be administered. This makes the POC studies highly cost-effective for Ambusol.

Below, to the left, Prof. Gunnar Ronquist reviews MRI-Scans of GBM patients and to the right visits a recently treated GBM patient in one of the hospitals.



KEY ADVANTAGES OF HOSPITALS

They treat exceptionally high patient volumes, ensuring fast recruitment, while their world-class neurosurgery and neuro-oncology expertise guarantee top-quality care. Each hospital has a proven track record in complex clinical trials, providing the infrastructure and credibility needed to advance Ambusol toward commercialization in one of the world's largest GBM markets.



HOSPITAL COMMITMENTS

Tiantan (Beijing): Leading neurosurgery center with strong interest in early-phase GBM trials.
Huashan (Shanghai): Experienced in global trials, focused on translational GBM research.
Xiangya (Changsha): Supports innovative therapies and capacity-building.
Renji (Shanghai): Interested in joining GBM research consortium and integrating novel therapies.

→ Funding and Clinical Trials Roadmap

● 2025 Q4

Current Round Close

Ambusol intends to close the current funding round during November 2025, raising up to 24,5 MSEK provided the overallotment right of 12,25 MSEK is also fully subscribed.

● 2026 Q4

Proof of Concept End

Complete treatment and monitoring of 10-40 patients in clinical proof of concept trials, generating internationally recognized data.

● 2027 Q1

Data & Regulatory Prep

Analyze proof of concept results and prepare regulatory submissions, including applications for Orphan Drug Designation in Europe, US, and Japan.

● 2027 Q2

Fundraise & Phase 3 studies

150–200 MSEK is raised to support Phase 3 trial with 100 patients across Asia and/or EU/US. For Chinese commercialization, this might not be needed since POC trials will be conducted there.

● 2027

Phase 3 & Expansion

Advance Phase 3 trials, leverage accelerated regulatory pathways, and drive global commercialization, while preparing to address additional cancer indications beyond GBM. Aim for full scale adoption of the treatment method.

A CLEARLY STRUCTURED and de-risked path that takes Ambusol from proof-of-concept trials (POC) through regulatory approvals and into full global commercialization, positioning the treatment for large-scale adoption and long-term growth.

→ Treatment Benefits vs Traditional Methods

THE AMBUSOL TREATMENT offers a revolutionary alternative to traditional glioblastoma therapies by significantly reducing treatment duration and eliminating adverse side effects, improving patient quality of life and outcomes.

AMBUSOL TREATMENT

- The treatment duration is only 7 days (one week), compared to traditional therapies that typically continue from diagnosis until recurrence, averaging about 13 months.
- No side effects, preserving patient quality of life throughout and after treatment.
- Targets metabolic vulnerabilities in aggressive cancer cells, causing selective self-destruction while sparing healthy cells.
- Unique patented catheter technology allows high-precision delivery and simultaneous clearance of necrotic tumor tissue.
- Reduced patient discomfort and fewer hospital visits due to the concise treatment and aftercare period.
- Has demonstrated a remarkable ability to extend survival, with two patients still living one 7.5 years after treatment and another 2.5 years, which is far beyond prognosis.

TRADITIONAL TREATMENT CHALLENGES

- Lengthy treatment protocols spanning about 13 months involving surgery, radiation, and chemotherapy (highly toxic treatment options), with adverse side effects for the patient.
- High recurrence rates despite aggressive therapy, with median survival of only 15 months post-prognosis.
- Non-specific targeting often damages surrounding healthy brain tissue, worsening patient outcomes.
- Extended hospital stays and frequent visits increase patient burden and healthcare costs.

SIDE EFFECTS

- Cognitive decline and neurological damage such as; memory loss, personality changes, speech problems, and permanent loss of brain function.
- Severe bone marrow suppression; infections, anemia, bleeding, extreme fatigue.
- Radiation necrosis and long-term brain damage; progressive loss of brain tissue function, most often irreversible.
- Extreme fatigue and physical weakness; persistent exhaustion from radiation, chemo, and steroids.
- Steroid-related complications; weight gain, diabetes, mood swings, insomnia, muscle wasting, and higher infection risk.

→ Intellectual Property - IP

AMBUSOL HAS A strong and growing IP portfolio. We are executing a deliberate and aggressive patent expansion into adjacent and new application areas. Continuous research and systematic invention harvesting provide a steady stream of filings, continuations, and defensive publications. This discipline secures freedom to operate, enables licensing opportunities, and strengthens our global presence. Together, these efforts build a lasting competitive advantage and deepen Ambusol's IP position.

METHOD PATENT - USA - FILED

- Built on Ambusol's artificial amino acid and protects the treatment approach for 25-year term, once granted.
- Forms part of the integrated, global patented catheter delivery technology, for precise intra-tumoral administration and simultaneous necrotic-tissue clearance.
- Complements overall IP strategy going forward.
- Strong synergy with EU/JPN/US entry in concert with Ambusol's Orphan Drug Designation strategy.

GLOBAL CATHETER IP PROTECTION THROUGH 5 PATENT FAMILIES

- Specialized, patented catheter enables localized, high-precision intra-tumoral delivery.
- Simultaneous extraction/clearance of necrotic tissue at the tumor site for better local control.
- Short 7-day regimen with no adverse side effects.

- Ongoing development and customization to enhance precision, safety, and usability.
- Increasing the IP portfolio through development within Ambusol's targeted cancer treatment areas; GBM, Prostate, Skin, Pancreas and Breast cancer.

ORPHAN DRUG DESIGNATION

- Exclusivity: 10 years in the EEA and Japan; 7 years in the U.S.
- Incentives: tax credits, reduced fees, and protocol assistance to support development.
- Faster pathways: access to accelerated/priority reviews that shorten time-to-market and patient access.
- Plan: leverage POC data and early regulator engagement to secure ODD across EEA, US, and Japan.
- Impact: bolsters brand credibility, protects against generic competition, and enhances investor confidence.

Summary of the Offer - Use of Funds- Estimated Outcome

AMBUSOL AB ("THE COMPANY") is a Swedish company founded in 2023 by Gunnar Ronquist, with the mission to offer a revolutionary treatment for the aggressive brain cancer Glioblastoma Multiforme (GBM). The company was founded with a primary vision to save lives. Since the project's inception in 1973, over 225,000 hours of research work have been invested by Gunnar Ronquist and his team consisting of 35 doctoral students and several international researchers with whom Gunnar Ronquist has collaborated over the years. Ambusol is now seeking capital, targeting its shareholders and a group of specially selected investors. Funds raised will be used as follows: Proof of Concept (POC) - clinical studies where the treatment will be administered to (up to 40 patients), to confirm its efficiency and safety, catheter development and software adaptation,

additional IP filings, application for Orphan Drug Designation (ODD) on the back of POC results and for ongoing operational costs. The negative outcome 2027 (175 and 167M SEK respectively, represents the cost for tentative phase 3 clinical trials).

AMBUSOL AIMS not only to change the landscape for GBM treatment but also aims to extend its research and treatment to other forms of cancer, where the method can be applied, those are: **prostate cancer, pancreatic cancer, skin cancer and breast cancer. A market with an overall combined treatment value of more than 60 billion USD in 2024. Budgets below only contains GBM sales and projected growth, with year 4 representing 2028.**

TRANSACTION HIGHLIGHTS



Company:	Ambusol AB (publ)
Instrument:	Common stock
Issue size:	12,25 MSEK with overallotment right of additional 12,25 MSEK
Valuation:	179 MSEK (pre money)
Minimum investment:	The subscription is made in minimum lots of SEK 10,500 (60 shares) and thereafter in multiples of 20 shares (SEK 3,500).
Price per share:	175 SEK

INVESTMENTS HIGHLIGHTS

✓	GBM treatment that takes only 7 days (one week) and costs less than half of the traditional treatment methods for GBM.
✓	Advanced cell therapy that selectively eradicates cells through cytolysis.
✓	A highly profitable method for Ambusol that is also beneficial for the patient .

Illustrated budget (MSEK)


Conservative




Budget Key Criteria

THE GLOBAL GBM patient population is projected to grow from approximately 300,000 in 2025 to 394,000 by 2035. Under this growth scenario, Ambusol has forecasted a projected 2035 market share of 3.49 % in the conservative case and 7.9 % in the base case.


Conservative - number of patients treated



Base case - number of patients treated




Net treatment revenue per patient (SEK)



→ Market Expansion Opportunities

ONCE AMBUSOLS GBM treatment is commercially established, the company plans to expand its innovative treatment platform to address other major high-growth cancer markets, unlocking significant additional commercial potential.



PROSTATE CANCER

Targeting an annual market projected to grow from \$14.71B in 2024 to \$34.28B by 2034, Ambusol aims to replicate its success in aggressive prostate cancer treatment.

PANCREATIC CANCER

With a \$2.92B market in 2024 expected to nearly double by 2030, pancreatic cancer presents a critical next step for Ambusol's targeted metabolic therapy.



BREAST CANCER

Breast cancer's large market, \$36.5B in 2024 growing to \$66.1B by 2034, offers substantial opportunity for growth using Ambusol's precise, low-side effect treatment approach.

SKIN CANCER

Ambusol targets the \$11.1B skin cancer market in 2024, expected to grow to \$22.9B by 2034, leveraging its patented drug delivery technology for localized treatment.



→ Competitor Overview

Modeyso

- Sold for: \$935M
- Target Market: 3,940 U.S. patients
- Efficacy: 22% response rate, 10 months average benefit (longer life), compared to traditional treatment methods
- Dosing: Once-weekly oral capsule
- Regulatory Status: FDA-approved
- Revenue Potential: Constrained by small patient pool and modest outcomes

MODEYSO IS AN FDA-approved therapy for Diffuse Midline Glioma (DMG), acquired for \$935 million. The asset addresses a highly specific and limited patient population, estimated at fewer than 4,000 individuals in the United States. While its once-weekly oral capsule formulation offers strong patient convenience, the treatment demonstrates only modest clinical efficacy, with response rates and durability of benefit constraining its overall therapeutic impact.

From a commercial standpoint, the opportunity is capped by both the rarity of the indication and the modest clinical outcomes observed, limiting the potential for meaningful revenue expansion. Although regulatory risk is minimal given its existing FDA approval, the established

profile also restricts upside potential. Overall, Modeyso represents a niche, low-growth asset-strategically valuable for addressing a rare disease need, but unlikely to deliver significant long-term financial returns beyond its narrow market.

→ Valuation & Development History

PROFESSOR EMERITUS Gunnar Ronquist has devoted his life to developing an effective and patient-friendly method to combat cancer. The formation of Ambusol is the result of a long and successful effort in medical research, where Professor Ronquist has played a crucial role for more than 50 years. During this period, Professor Ronquist, together with researchers from Sweden, Greece, USA, and India, has not only dedicated over 150,000 hours to his own research in the field but has also been a mentor and supervisor for 35 PhD students who have completed their doctoral dissertations in the field. Alongside Professor Ronquist's own research, over 225,000 hours have been devoted to developing and refining Ambusol's method. These joint efforts have resulted in a deep and comprehensive understanding of the field, which in turn has paved the way for the revolutionary treatment method Ambusol possesses today.

There are many different methods to value a company and/or an innovation. In the present offer, we have chosen to apply a very simple method, namely valuing the resources spent on development and what they are worth. Qualified research costs money, both in terms of equipment and materials, but also in time spent. In this valuation model, we have disregarded the considerable direct investments made over the years as well as the purchase of necessary materials and other expenses, such as laboratory time. We have also not considered the significant and in many respects revolutionary results achieved with the treatment method, which represents by far the greatest

value in the company. Nor have we considered the global and exclusive license agreement entered with Flucell, a public life science company, with a unique, state of the art and world-wide patented fluid distribution platform for the exclusive use by Ambusol within our designated cancer treatment areas. Not only consisting of GBM, but also Prostate cancer, Pancreatic cancer, Skin cancer and Breast cancer were Ambusol's treatment method is suitable. Together in 2024, totaling a combined treatment value of more than 600 billion SEK.

WE HAVE CHOSEN to disregard all this including the potential upside and solely focus on the time invested in the project. Since the research has been ongoing for many years and costs have risen over the period, we have chosen to apply a unit price per research hour of 1,000 SEK. Given this, Ambusol is valued at 225 million SEK, after which we have discounted the value further and set the final company valuation at 179 million SEK (pre-money) in the present offer (including some 4 million SEK) invested since the inception of the company.

The general cost of developing a drug today amounts to between 3.14 and 28 billion SEK. The largest part of this cost consists of research and development (R&D) and clinical studies with

thousands of patients over a ten-year period or more. This due to the fact the method and/or medicine is of generic character, i.e. treats a symptom where there are many other alternatives on the market. In Ambusol's case, the research has spanned over many years and has been conducted almost exclusively within the academic world and not in a commercial company, such as for instance when Astra developed the ulcer medication, Losec.

SINCE AMBUSOL'S method has been scientifically proven on patients, is far more beneficial and treats a RARE disease, i.e. GBM - all medical approval institutions for instance Federal Drug Administration, USA (FDA) and European Medical Association, Europe (EMA) and National Medical Products Administration, China (NMPA), have all agreed on expedited regulatory approval, based on the significant patient value. This eliminates the uncertainty and otherwise lengthy approval procedures for a traditional treatment method, that is one of many other alternatives.

A successful Proof of Concept Study, is expected to increase current valuation by 5-10 X.



→ Main Terms

Issuer:	Ambusol AB (publ)
LEI-code:	636700XNUHQ9LDSISN71
Instrument:	Common shares, only one class of shares exists in the Company
Issue size:	12,25 MSEK, corresponding to 70,000 new shares, with an overallotment right of additional 70,000 shares
Subscription period:	6 October - 17 November 2025
Notice of allocation:	Announced through the dispatch of a contract note
Payment:	Payment instructions are stated on the dispatched contract note
Subscription:	The issue is directed to the shareholders and a selected group of investors
Price:	175 SEK per share
Valuation:	179 MSEK (pre money)
Minimum investment:	10,500 SEK (60 shares) and thereafter in multiples of (20 shares), 3,500 SEK
Purpose:	POC for clinical studies, catheter development/adaptation, ODD application, additional IP filings and operational costs
Reporting:	The company reports annually in the form of an annual audited report
Exit:	Planned investor exit during 2029-2032 through the sale of the Company to a larger entity or via an IPO
Votes:	One vote per share
Registration:	The Company is Euroclear connected
Fee:	The advisor, if applicable, will be paid a fee by the Company after the transaction is completed, based on the outcome

→ Terms and conditions

The Offer

The offer comprises of 70,000 shares with an overallotment right of additional 70,000 shares, each with one (1) vote per share and equal rights to the company's profits. Upon full subscription, including the overallotment right, the number of shares in the company will increase from the current 1,022,103 up to 1,162,103. The dilution for shareholders who do not participate in the issue under such conditions will be approximately 12.05%, calculated as the maximum number of new shares divided by the total number of shares after the fully subscribed new issue, including the overallotment right. The offer has been prepared in accordance with Swedish legislation.

Preferential Right to Subscription

The shares are issued without preferential rights for existing shareholders.

Issue Price

The new shares are issued at a price of 175 SEK per share. No brokerage fees or taxes will be added to this amount. The issue price has been determined by the board and is based on the resources expended in the form of direct work hours that Professor Ronquist has dedicated since he began his research in the field in 1973. Additionally, it includes the hours invested by more than 35 PhD students whom Professor Ronquist has supervised over the years, following research in the GBM field.

Subscription Lot

Shares are subscribed in a minimum lot of 10,500 kronor (60 shares) and thereafter in multiples of 3,500 kronor (20 shares).

Subscription Period

Subscription for new shares must be made in the manner specified below during the period from 6 October - 17 November 2025, with the board having the right to extend the subscription period.

Application Form

The application form is provided separately from this document. The easiest way to subscribe is electronically via bank-ID at: www.aqurat.se/ambusol-ab-publ. The application form can also be ordered free of charge from the Company or from the Company's issuing institution listed below.

The application form and other documents are also available for download on the Company's website, www.ambusol.se or at: www.aqurat.se/ambusol-ab-publ. Incomplete or incorrectly filled application forms may be disregarded. Only one (1) application form per individual or legal entity will be considered. If more than one application form is submitted, only the most recently received will be considered. Applications for subscription of shares are binding.

Completed application forms must be received by Aqurat Fondkommission no later than 17:00 on 17th of November 2025. Application forms sent by mail should be dispatched well before the last day of the application period.

Those applying for the acquisition of shares must have a VP account or a depot with a bank or other manager to which the delivery of shares can be made. Persons without a VP account or depot must open a VP account or depot with a bank or securities institution before submitting the application form as per the above instructions. Please note that it may take some time to open a VP account or depot. Also, note that those who have a depot or account with specific rules for securities transactions, such as an investment savings account (ISK) or capital insurance account (KF), must check with the bank/manager maintaining the account whether, and if so how, acquisition of securities within the framework of the offer is possible. The application must, in such cases, be made in consultation with the bank/manager maintaining the account.

Allocation

The allocation of shares will be decided by the board of Ambusol AB, and the following principles shall apply:

- a. In the event of oversubscription, allocation may be made for a lower number of shares than applied for, or may be entirely omitted, depending on the date the subscription application was received.
- b. The allocation may be decided entirely at the board's discretion.

There is no upper limit to the number of shares an individual subscriber can apply for, within the limits of the new issue. Notification of allocation will be sent by mail by Aqurat Fondkommission to the address provided on the application form, or by email if such an address has been provided.

Payment and Delivery of Shares

Payment must be made according to the instructions from Aqurat Fondkommission following the allocation notification. Full payment for allocated shares must be made in cash according to the instructions on the contract note. Shares that are not paid for on time may be transferred to another party. Compensation may be required from those who have not paid for subscribed shares.

Delivery of Shares

As soon as the issuance is registered with the Swedish Companies Registration Office, which is expected to occur during week 48 (November 24-28), 2025. After this, the shares subscribed in the issuance will be delivered to the VP account or depot with a bank or other manager specified on the application form. In connection with this, the subscriber will receive a VP notice confirming that the securities have been booked into their VP account. Holders with their holdings registered in a depot with a bank or other manager will receive information from their respective manager.

Trading in the Shares – Investor Exit

Currently, there is no organized trading in the shares. The board's plan is for an exit to occur either through the sale of the company to an industry player or through listing the company's shares on a Swedish or international trading platform (stock exchange). The goal, provided that the company develops according to plan, is for the exit to occur during the period 2029– 2032.

Restrictions Regarding Participation in the Offer

Due to securities legislation restrictions in the USA, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, and Japan, the offer to subscribe for shares is not directed to persons or entities with a registered address in any of these countries.

Right to Dividends

The new shares entitle holders to dividends from the record date for the dividend decided upon immediately after the registration of the current new issue. All shares have the same right to dividends. There are no restrictions on the right to dividends. Any dividend payments are handled by Euroclear Sweden AB or, for nominee-registered holdings, in accordance with the respective nominee's procedures. If shareholders cannot be reached, the shareholder's claim on the company for the dividend amount remains and is only limited by the statutes of limitations.

Share Register

The company's share register is administered by and accounted for by Euroclear at the address Euroclear Sweden AB, Box 191, SE-101 23 Stockholm, Sweden.

Publication of the Outcome of the Offer

The results of the offer will be announced through a press release on November 28, 2025. The press release will be published on the company's website.

Additional Information

This summary of the full Memorandum has been prepared by the board of the company, which is also responsible for marketing the issuance. The shares in Ambusol are not subject to an offer resulting from mandatory bids, redemption rights, or redemption obligations. There has been no public takeover bid during the current or previous financial year. Newly issued shares entitle the holder to the same share of the company's profits and any dividends, including in the event of liquidation, as existing shares. All shares in the company have the same voting value, i.e., one (1) vote per share held.

Shareholders' rights regarding profit distribution, voting rights, preferential rights in the event of new share subscriptions, and more, are governed by the company's articles of association.

→ Contact Details

ISSUER:
AMBUSOL AB (PUBL)

Humlegårdsgatan 4
114 46 Stockholm, SWEDEN

Phone: +46-70 750 54 71

Email for inquiries: max@ambusol.com

ISSUING INSTITUTION:
AQRAT FONDKOMMISSION AB

Kungsgatan 58, 111 22 Stockholm,
SWEDEN

Phone: +46 8 684 058 00 for support

Email: info@aqurat.se for general
questions

ACCOUNT-HOLDING INSTITUTION:
EUROCLEAR SWEDEN AB

Box 191, 101 12 Stockholm, SWEDEN

Phone: +46 8 402 90 00 for agent
services

Provides settlement and custody services for securities